Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Discovery Clinical Trials

Neither a doctor nor a teaching hospital

Research payments

$2,219,589

916 payments

Through program year 2025, Discovery Clinical Trials is reported as receiving $2,219,589 in research payments, across 916 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $525,363 324
2024 Research $398,610 242
2023 Research $111,556 22
2022 Research $211,730 56
2021 Research $149,836 39
2020 Research $461,799 115
2019 Research $360,695 118

Breakdown

Who paid Research payments · program years 2019–2025
  1. Sumitomo Pharma America, Inc. $668,638 537 payments
  2. Sanofi US Services Inc. $359,386 122 payments
  3. Novartis Pharmaceuticals Corporation $327,097 13 payments
  4. Amgen Inc. $193,151 10 payments
  5. GlaxoSmithKline, LLC. $187,969 91 payments
  6. Eisai Inc. $125,011 18 payments
  7. Ironwood Pharmaceuticals, Inc $107,018 60 payments
  8. AstraZeneca UK Limited $91,105 3 payments
  9. Genentech, Inc. $23,378 8 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $17,700 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids Or Endometriosis $668,638 537 payments
  2. Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $283,107 9 payments
  3. A 56-week, Multicenter, Open-label, Active-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly Compared to Dulaglutide Once Weekly in Patients with Type 2 Dia $259,806 81 payments
  4. FOURIER OLE (Ph 4) $144,107 7 payments
  5. A 52 Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belviq XR??in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years $125,011 18 payments
  6. A 52-Week, Randomised, Double-Blind, Double-Dummy, Parallel Group, Mul $96,145 45 payments
  7. McP-103-312 $92,597 52 payments
  8. a phase two a,randomized,double blind,placebo controlled study to assess efficacy and safety of atuliflapon given orally once daily for twelve weeks in adults with moderate to severe uncontrolled asthma $73,681 1 payment
  9. A 56-week, Multicenter, Open-label, Active-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly Compared to Dulaglutide Once Weekly in Patients with Type 2 Dia $69,705 27 payments
  10. A 52-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel-Grou $53,543 29 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record